<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927784</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 08-1093</org_study_id>
    <secondary_id>P50HL077096</secondary_id>
    <nct_id>NCT00927784</nct_id>
  </id_info>
  <brief_title>Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVAD</brief_title>
  <official_title>The Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Bridge to Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Angioblast Systems</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Left ventricular assist devices (LVADs) are one treatment option for people with congestive
      heart failure. This study will evaluate the safety of injecting mesenchymal precursor cells
      (MPCs) into the heart during LVAD implantation surgery and examine if injecting MPCs into the
      heart is effective at improving heart function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Congestive heart failure is a major health problem and recent estimates indicate that
      end-stage heart failure with a 2-year mortality rate of 70-80% affects over 60,000 people in
      the United States each year. For these patients, treatment options are extremely limited.
      Less than 3,000 heart transplants are available each year because of the severely limited
      supply of donor hearts. Implantable LVADs, routinely used to support heart transplantation
      patients who decompensate awaiting a donor heart, were approved by the Food and Drug
      Administration (FDA) in 2002 for long-term support when heart transplantation is not an
      option. Few patients, however, achieve sufficient recovery to warrant LVAD explantation and
      those who do must still contend with ventricular dysfunction. MPCs are normally present in
      human bone marrow and have been shown to increase the development of blood vessels and new
      heart muscle cells. The purpose of this study is to determine the safety of injecting MPCs
      into the heart during LVAD implantation surgery. In addition, this study will examine whether
      injecting MPCs into the heart is effective at improving heart function.

      This study will enroll people who are on the waiting list to receive a donor heart and who
      are undergoing LVAD implantation surgery. Before the surgery, participants will be randomly
      assigned to one of two groups. One group of participants will have MPCs injected into their
      heart during LVAD surgery and the other group of participants will have a control solution
      (placebo) injected into their heart during the surgery. A portion of heart muscle removed
      during the surgery will be analyzed. Participants will be monitored by study researchers and
      blood samples will be collected 12 hours after the LVAD surgery and at 1, 7, 21, 60, and 90
      days after the surgery. After that, a medical history review, physical examination, and blood
      collection will occur every 60 days until a heart transplant occurs or until 12 months after
      the LVAD implantation, whichever comes first. Heart function testing, which will include an
      echocardiogram, neuronal function testing, and a 6-minute walk test, will occur 60 and 90
      days after the LVAD implantation, and every 2 months thereafter until a heart transplant
      occurs or until 12 months after the LVAD implantation, whichever comes first.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The enrollment has been terminated by the NHLBI for administrative reasons.
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Infectious Myocarditis</measure>
    <time_frame>Measured within 90 days of study entry</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Myocardial Rupture</measure>
    <time_frame>Measured within 90 days of study entry</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Neoplasm</measure>
    <time_frame>Measured within 90 days of study entry</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Hypersensitivity Reaction</measure>
    <time_frame>Measured within 90 days of study entry</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Immune Sensitization</measure>
    <time_frame>Measured within 90 days of study entry</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of LVAD Wean</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The secondary endpoints assessed during the LVAD wean include echocardiographic assessments, 6 minute walk, ability to tolerate wean from LVAD support, duration of ability to tolerate wean from LVAD support, and neuronal function.
Measured at 60 days, 90 days, and every 60 days thereafter following LVAD implantation until heart transplantation or 12 months, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Study Intervention-related Adverse Events</measure>
    <time_frame>up to 12 months</time_frame>
    <description>This includes Device Malfunction-Pump Thrombus-Suspected and Internal Pump Component, Inflow, or Outflow Tract Infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of All Serious Adverse Events</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Experienced Donor-specific HLA Sensitization</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Number of patients who experienced donor-specific HLA sensitization post-randomization in each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Myocardial Neovascularization at Time of Explant</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Cardiomyocyte Regeneration at Explant</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Cell Engraftment and Fate at Explant</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Survival to Cardiac Transplantation</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Cryoprotective media alone</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants will receive intramyocardial injections of cryoprotective media alone (placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mesenchymal Precursor cells (RevascorTM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs in sequential cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal Precursor cells (RevascorTM)</intervention_name>
    <description>Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs (in sequential cohorts).</description>
    <arm_group_label>Mesenchymal Precursor cells (RevascorTM)</arm_group_label>
    <other_name>Mesenchymal Precursor cells</other_name>
    <other_name>RevascorTM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cryoprotective media alone</intervention_name>
    <description>Participants will receive intramyocardial injections of cryoprotective media (placebo).</description>
    <arm_group_label>Cryoprotective media alone</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent, release of medical information, and Health Insurance
             Portability and Accountability Act (HIPAA) documents

          -  Age 18 years or older

          -  If the participant or partner is of childbearing potential, he or she must be willing
             to use adequate contraception (hormonal or barrier method or abstinence) from the time
             of screening and for a period of at least 16 weeks after LVAD implantation

          -  Female participants of childbearing potential must have a negative serum pregnancy
             test at screening

          -  Admitted to the clinical center at the time of study entry

          -  Listed with the United Network for Organ Sharing (UNOS) for heart transplantation

          -  Clinical indication and accepted candidate for implantation of an FDA- approved LVAD
             as a bridge to transplantation

        Exclusion Criteria:

          -  Cardiothoracic surgery within 30 days of study entry

          -  Heart attack within 30 days of study entry

          -  Prior heart transplantation, left ventricular (LV) reduction surgery, or
             cardiomyoplasty

          -  Acute reversible cause of heart failure (e.g., myocarditis, profound hypothyroidism)

          -  Anticipated requirement for biventricular mechanical support

          -  Stroke within 30 days of study entry

          -  Received investigational intervention within 30 days of study entry

          -  Platelet count less than 100,000/uL within 24 hours of study entry

          -  Active systemic infection within 48 hours of study entry

          -  Presence of greater than 10% anti-human leukocyte antigen (HLA) antibody titers with
             known specificity to the MPC donor HLA antigens

          -  Known hypersensitivity to dimethyl sulfoxide (DMSO), murine, and/or bovine products

          -  History of cancer prior to screening (excluding basal cell carcinoma)

          -  Acute or chronic infectious disease, including but not limited to human
             immunodeficiency virus (HIV)

          -  Treatment and/or an incompleted follow-up treatment of any investigational therapy
             within 6 months of study entry

          -  Active participation in other research therapy for cardiovascular repair/regeneration

          -  Prior recipient of stem precursor cell therapy for cardiac repair

          -  Pregnant or breastfeeding at the time of study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Ascheim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yoshifumi Naka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sharp Memorial Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 23, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <results_first_submitted>June 13, 2013</results_first_submitted>
  <results_first_submitted_qc>February 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2019</results_first_posted>
  <last_update_submitted>February 28, 2019</last_update_submitted>
  <last_update_submitted_qc>February 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Annetine Gelijns</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Mesenchymal Precursor Cells</keyword>
  <keyword>Left Ventricular Assist Device</keyword>
  <keyword>LVAD</keyword>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>80 patients with end-stage CHF and clinical indication for implantation with an FDA-approved LVAD as a bridge-to-transplant were to be enrolled. 40 patients in the low dose cohort(25M)/40 patients in the high dose cohort(75M). Trial enrollment was permanently suspended upon 10 patients enrolled in the low dose cohort due to a change in NIH funding.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose Cohort: Treatment Group</title>
          <description>Intramyocardial injection of study drug (25 million MPC) (Revasacor TM)at the time of LVAD implantation</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Cohort: Control Group</title>
          <description>Intramyocardial injection of vehicle (50% alpha-MEM/42.5% proFreeze NAO Freezing Medium/7.5%DMSO) at the time of LVAD implantation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose Cohort: Treatment Group</title>
          <description>Intramyocardial injection of study drug (25 million MPC) (Revasacor TM)at the time of LVAD implantation</description>
        </group>
        <group group_id="B2">
          <title>Low Dose Cohort: Control Group</title>
          <description>Intramyocardial injection of vehicle (50% alpha-MEM/42.5% proFreeze NAO Freezing Medium/7.5%DMSO) at the time of LVAD implantation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="14"/>
                    <measurement group_id="B2" value="51" spread="5"/>
                    <measurement group_id="B3" value="55" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Infectious Myocarditis</title>
        <time_frame>Measured within 90 days of study entry</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Cohort: Treatment Group</title>
            <description>Intramyocardial injection of study drug (25 million MPC) (Revasacor TM)at the time of LVAD implantation</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Cohort: Control Group</title>
            <description>Intramyocardial injection of vehicle (50% alpha-MEM/42.5% proFreeze NAO Freezing Medium/7.5%DMSO) at the time of LVAD implantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Infectious Myocarditis</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Myocardial Rupture</title>
        <time_frame>Measured within 90 days of study entry</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Cohort: Treatment Group</title>
            <description>Intramyocardial injection of study drug (25 million MPC) (Revasacor TM)at the time of LVAD implantation</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Cohort: Control Group</title>
            <description>Intramyocardial injection of vehicle (50% alpha-MEM/42.5% proFreeze NAO Freezing Medium/7.5%DMSO) at the time of LVAD implantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Myocardial Rupture</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Neoplasm</title>
        <time_frame>Measured within 90 days of study entry</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Cohort: Treatment Group</title>
            <description>Intramyocardial injection of study drug (25 million MPC) (Revasacor TM)at the time of LVAD implantation</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Cohort: Control Group</title>
            <description>Intramyocardial injection of vehicle (50% alpha-MEM/42.5% proFreeze NAO Freezing Medium/7.5%DMSO) at the time of LVAD implantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Neoplasm</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Hypersensitivity Reaction</title>
        <time_frame>Measured within 90 days of study entry</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Cohort: Treatment Group</title>
            <description>Intramyocardial injection of study drug (25 million MPC) (Revasacor TM)at the time of LVAD implantation</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Cohort: Control Group</title>
            <description>Intramyocardial injection of vehicle (50% alpha-MEM/42.5% proFreeze NAO Freezing Medium/7.5%DMSO) at the time of LVAD implantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hypersensitivity Reaction</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Immune Sensitization</title>
        <time_frame>Measured within 90 days of study entry</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Cohort: Treatment Group</title>
            <description>Intramyocardial injection of study drug (25 million MPC) (Revasacor TM)at the time of LVAD implantation</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Cohort: Control Group</title>
            <description>Intramyocardial injection of vehicle (50% alpha-MEM/42.5% proFreeze NAO Freezing Medium/7.5%DMSO) at the time of LVAD implantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Immune Sensitization</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of LVAD Wean</title>
        <description>The secondary endpoints assessed during the LVAD wean include echocardiographic assessments, 6 minute walk, ability to tolerate wean from LVAD support, duration of ability to tolerate wean from LVAD support, and neuronal function.
Measured at 60 days, 90 days, and every 60 days thereafter following LVAD implantation until heart transplantation or 12 months, whichever comes first</description>
        <time_frame>up to 12 months</time_frame>
        <population>data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Cohort: Treatment Group</title>
            <description>Intramyocardial injection of study drug (25 million MPC) (Revasacor TM)at the time of LVAD implantation</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Cohort: Control Group</title>
            <description>Intramyocardial injection of vehicle (50% alpha-MEM/42.5% proFreeze NAO Freezing Medium/7.5%DMSO) at the time of LVAD implantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of LVAD Wean</title>
          <description>The secondary endpoints assessed during the LVAD wean include echocardiographic assessments, 6 minute walk, ability to tolerate wean from LVAD support, duration of ability to tolerate wean from LVAD support, and neuronal function.
Measured at 60 days, 90 days, and every 60 days thereafter following LVAD implantation until heart transplantation or 12 months, whichever comes first</description>
          <population>data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Study Intervention-related Adverse Events</title>
        <description>This includes Device Malfunction-Pump Thrombus-Suspected and Internal Pump Component, Inflow, or Outflow Tract Infection</description>
        <time_frame>up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Cohort: Treatment Group</title>
            <description>Intramyocardial injection of study drug (25 million MPC) (Revasacor TM)at the time of LVAD implantation</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Cohort: Control Group</title>
            <description>Intramyocardial injection of vehicle (50% alpha-MEM/42.5% proFreeze NAO Freezing Medium/7.5%DMSO) at the time of LVAD implantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Study Intervention-related Adverse Events</title>
          <description>This includes Device Malfunction-Pump Thrombus-Suspected and Internal Pump Component, Inflow, or Outflow Tract Infection</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of All Serious Adverse Events</title>
        <time_frame>up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Cohort: Treatment Group</title>
            <description>Intramyocardial injection of study drug (25 million MPC) (Revasacor TM)at the time of LVAD implantation</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Cohort: Control Group</title>
            <description>Intramyocardial injection of vehicle (50% alpha-MEM/42.5% proFreeze NAO Freezing Medium/7.5%DMSO) at the time of LVAD implantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All Serious Adverse Events</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Experienced Donor-specific HLA Sensitization</title>
        <description>Number of patients who experienced donor-specific HLA sensitization post-randomization in each treatment arm.</description>
        <time_frame>up to 12 months</time_frame>
        <population>Study terminated early. Data not collected or analyzed for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Cohort: Treatment Group</title>
            <description>Intramyocardial injection of study drug (25 million MPC) (Revasacor TM)at the time of LVAD implantation</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Cohort: Control Group</title>
            <description>Intramyocardial injection of vehicle (50% alpha-MEM/42.5% proFreeze NAO Freezing Medium/7.5%DMSO) at the time of LVAD implantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Experienced Donor-specific HLA Sensitization</title>
          <description>Number of patients who experienced donor-specific HLA sensitization post-randomization in each treatment arm.</description>
          <population>Study terminated early. Data not collected or analyzed for this Outcome Measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Myocardial Neovascularization at Time of Explant</title>
        <time_frame>up to 12 months</time_frame>
        <population>Study terminated early. Data not collected or analyzed for this Outcome Measure</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Cohort: Treatment Group</title>
            <description>Intramyocardial injection of study drug (25 million MPC) (Revasacor TM)at the time of LVAD implantation</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Cohort: Control Group</title>
            <description>Intramyocardial injection of vehicle (50% alpha-MEM/42.5% proFreeze NAO Freezing Medium/7.5%DMSO) at the time of LVAD implantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Myocardial Neovascularization at Time of Explant</title>
          <population>Study terminated early. Data not collected or analyzed for this Outcome Measure</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Cardiomyocyte Regeneration at Explant</title>
        <time_frame>up to 12 months</time_frame>
        <population>Study terminated early. Data not collected or analyzed for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Cohort: Treatment Group</title>
            <description>Intramyocardial injection of study drug (25 million MPC) (Revasacor TM)at the time of LVAD implantation</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Cohort: Control Group</title>
            <description>Intramyocardial injection of vehicle (50% alpha-MEM/42.5% proFreeze NAO Freezing Medium/7.5%DMSO) at the time of LVAD implantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Cardiomyocyte Regeneration at Explant</title>
          <population>Study terminated early. Data not collected or analyzed for this Outcome Measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Cell Engraftment and Fate at Explant</title>
        <time_frame>up to 12 months</time_frame>
        <population>Study terminated early. Data not collected or analyzed for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Cohort: Treatment Group</title>
            <description>Intramyocardial injection of study drug (25 million MPC) (Revasacor TM)at the time of LVAD implantation</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Cohort: Control Group</title>
            <description>Intramyocardial injection of vehicle (50% alpha-MEM/42.5% proFreeze NAO Freezing Medium/7.5%DMSO) at the time of LVAD implantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Cell Engraftment and Fate at Explant</title>
          <population>Study terminated early. Data not collected or analyzed for this Outcome Measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Survival to Cardiac Transplantation</title>
        <time_frame>up to 12 months</time_frame>
        <population>Study terminated early. Data not collected or analyzed for this Outcome Measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Cohort: Treatment Group</title>
            <description>Intramyocardial injection of study drug (25 million MPC) (Revasacor TM)at the time of LVAD implantation</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Cohort: Control Group</title>
            <description>Intramyocardial injection of vehicle (50% alpha-MEM/42.5% proFreeze NAO Freezing Medium/7.5%DMSO) at the time of LVAD implantation.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Survival to Cardiac Transplantation</title>
          <population>Study terminated early. Data not collected or analyzed for this Outcome Measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Continuous from randomization until induction of anesthesia for cardiac transplant or 12 months, whichever comes first.</time_frame>
      <desc>Adverse events were documented and reported by staff at the study sites as they occurred per the protocol definitions. All adverse events were adjudicated by an Independent Clinical Events Committee (CEC).</desc>
      <group_list>
        <group group_id="E1">
          <title>Low Dose Cohort: Treatment Group</title>
          <description>Intramyocardial injection of study drug (25 million MPC) (Revasacor TM)at the time of LVAD implantation</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Cohort: Control Group</title>
          <description>Intramyocardial injection of vehicle (50% alpha-MEM/42.5% proFreeze NAO Freezing Medium/7.5%DMSO) at the time of LVAD implantation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Intra-operative Bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Major Bleeding (Non-Intra-Operative)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Venous Thromboembolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Other Bleeding</sub_title>
                <description>elevated INR, epistaxis and bloody stools</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Device Malfunction-Pump Thrombus-Suspected</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmias</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Other (Volume Overload)</sub_title>
                <description>Volume overload</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Other (decompensated heart failure)</sub_title>
                <description>decompensated heart failure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Right Heart Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Other (New diagnosis of Type II diabetes)</sub_title>
                <description>New diagnosis of Type II diabetes</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Major Infection - Percutaneous Site Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Major Infection - Internal Pump Component, Inflow, or Outflow Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological Dysfunction - Ischemic Stroke</sub_title>
                <description>Ischemic stroke</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neurological Dysfunction - TIA</sub_title>
                <description>TIA</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neurological Dysfunction - Other</sub_title>
                <description>focal seizures</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Dysfunction - Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Other (vasodilatory shock periop)</sub_title>
                <description>vasodilatory shock periop</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The site investigators have the right to independently publish results of their portion of the study conducted at their site 1 year following study conclusion; the site investigator must submit to the DCC for review and comment,a copy of any proposed manuscript resulting from research at least thirty (30) days prior to estimated publication date. If no response is received within thirty (30) days of the date the manuscript was submitted to the DCC, publication may proceed without delay.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>After the 10th patient was enrolled,enrollment was permanently suspended due to a change in NIH funding. Enrollment activity ceased and study was terminated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Deborah Ascheim, MD, Principal Investigator, Data Coordinating Center</name_or_title>
      <organization>Mount Sinai School of Medicine</organization>
      <phone>212-659-9567</phone>
      <email>deborah.ascheim@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

